Literature DB >> 3838676

Selective labelling of M1-receptors in autonomic ganglia with 3H-pirenzepine.

E Giraldo, E Monferini, R Hammer.   

Abstract

Using the classical muscarinic antagonist 3H-N-methyl-scopolamine as radioligand and unlabelled pirenzepine (PZ) as displacing agent, a heterogeneous muscarinic receptor population consisting of about 70% M1-receptors and 30% M2-receptor, can be demonstrated in crude membranes of calf sympathetic ganglia. In the same preparation only low and variable specific binding is detectable when 3H-PZ is used as marker ligand. The situation clearly improves when synaptosomes are prepared from the ganglia. Then binding of 3H-PZ can be measured with a favourable specific to non specific binding ratio and with features compatible with the selective labelling of ganglionic M1-receptor sites. It is concluded that the 3H-PZ binding assay in synaptosomes of autonomic ganglia is a novel method for the characterization of the peripheral M1-receptor.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3838676

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  4 in total

1.  Dose-response curves of pirenzepine in man in relation to M1- and M2-cholinoceptor occupancy.

Authors:  H F Pitschner; A Wellstein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-08       Impact factor: 3.000

2.  Pharmacological differences between two muscarinic responses of the rat superior cervical ganglion in vitro.

Authors:  N R Newberry; T Priestley
Journal:  Br J Pharmacol       Date:  1987-12       Impact factor: 8.739

3.  Complex dose-response curves of atropine in man explained by different functions of M1- and M2-cholinoceptors.

Authors:  A Wellstein; H F Pitschner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-07       Impact factor: 3.000

4.  Binding and functional profiles of the selective M1 muscarinic receptor antagonists trihexyphenidyl and dicyclomine.

Authors:  A Giachetti; E Giraldo; H Ladinsky; E Montagna
Journal:  Br J Pharmacol       Date:  1986-09       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.